Israel’s COVID vaccine candidate ‘Brilife’ brings new hopes
Israel has named its COVID-19 vaccine candidate ‘Brilife’ and its human trials will start by October-end, as per an official public statement.
The beginning of human trials has been described as a “very significant moment” and “source of national pride” by Defence Minister Benny Gantz. Israel Institute of Biological Research (IIBR) is working on the prospective vaccine. ‘Brilife’ is a mixture of the Hebrew word “Bri” (health) and “il” (the internet country code for Israel) and “life”, IIBR Director Shmuel Shapira said.
The duration of human trials and when will the vaccine be available for use has not been specified yet. Israel set out to develop the vaccine on February 2 and great efforts have been taken to prepare it since then.